Anzeige
Mehr »
Login
Mittwoch, 19.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Doppeltes “STRONG BUY”! Jetzt bei EAM einsteigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PMPH | ISIN: US83558L2043 | Ticker-Symbol: O8Z3
Tradegate
19.06.24
10:21 Uhr
0,162 Euro
-0,020
-10,99 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SONOMA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SONOMA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1550,16313:01
0,1550,16310:22

Aktuelle News zur SONOMA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoSonoma Pharmaceuticals GAAP EPS of -$0.07 beats by $0.10, revenue of $3.44M misses by $0.54M7
MoSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results351Revenues increased 14% in Q4 2024 compared to Q4 2023Gross profit margin improved 3% in FY 2024 compared to FY 2023Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to...
► Artikel lesen
MoSonoma Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
MoSonoma Pharmaceuticals, Inc. - 10-K, Annual Report3
09.05.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores594BOULDER, CO / ACCESSWIRE / May 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid...
► Artikel lesen
09.04.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States382BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
09.04.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report3
04.04.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections296BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
02.04.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report1
28.03.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences276BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
27.03.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals287BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
22.03.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report1
08.03.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report5
12.02.Sonoma Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary6
08.02.Sonoma Pharmaceuticals GAAP EPS of -$0.08 beats by $0.13, revenue of $3.14M misses by $0.62M2
08.02.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results473Revenues increased 7% compared to quarter from prior year and 15% from prior quarterImprovement in gross margin for quarter of 19% compared to prior yearImprovement in net loss for quarter of $1.0 million...
► Artikel lesen
08.02.Sonoma Pharmaceuticals, Inc. - 10-Q, Quarterly Report-
23.01.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use537BOULDER, CO / ACCESSWIRE / January 23, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
09.01.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report7
09.01.Sonoma Pharmaceuticals, Inc.: NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network602EMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. (NYSE American:NBY) and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1